다케다약품공업 ADR (TAK)

개요 뉴스 가격 이력 옵션 체인 토론 예측 배당 이력

Relative Volume:

다케다약품공업 ADR Stock (TAK) Company Profile

Takeda Pharmaceutical Co Adr

Healthcare (1169)

@takedapharma

최신 SEC 제출 서류

TAK's Discussions on Twitter

TAK을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
TAK Takeda Pharmaceutical Co Adr	14.06	44.58B	30.25B	1.37B	5.08B	0.4257
ZTS Zoetis Inc	160.46	71.85B	9.26B	2.49B	2.30B	5.47
HLN Haleon Plc Adr	10.08	45.58B	14.26B	1.55B	0	0.3383
TEVA Teva Pharmaceutical Industries Ltd Adr	16.74	19.18B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	128.60	13.67B	612.78M	-86.37M	-62.91M	-0.87

다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-03-16	업그레이드	BofA Securities	Neutral → Buy
2022-07-19	업그레이드	Cowen	Market Perform → Outperform
2021-10-07	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-04-19	다운그레이드	JP Morgan	Overweight → Neutral
2019-11-01	개시	Cowen	Market Perform
2019-08-15	다운그레이드	Daiwa Securities	Outperform → Neutral

다케다약품공업 ADR 주식(TAK)의 최신 뉴스

다케다약품공업 ADR (TAK) 재무 분석

다케다약품공업 ADR (TAK)

다케다약품공업 ADR Stock (TAK) Company Profile

TAK을(를) 다른 주식과 비교

다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades

다케다약품공업 ADR 주식(TAK)의 최신 뉴스

Yaqrit strengthens board and senior management ahead of multi-prong clinical push in advanced liver disease - GlobeNewswire Inc.

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN

TAK vs. DSNKY: Which Stock Is the Better Value Option? - Nasdaq

Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN

IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR

IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, - openPR

Procter & Gamble Co (PG) expanding its growth trajectory ahead - SETE News

Prepare Yourself for Liftoff: AMKOR Technology Inc (AMKR) - SETE News

Takeda Pharmaceutical Co ADR [TAK] President, Plasma-Derived Ther makes an insider purchase of 19,073 shares worth 0.28 million. – Knox Daily - Knox Daily

Advanced Drainage Systems Inc [WMS] Records 50-Day SMA of $122.78 - Knox Daily

GFL Shares Experience Surge in Value - Knox Daily

UBS Group AG [UBS] Shares Rise 2.39 % on Thursday - Knox Daily

Takeda Pharmaceutical Co ADR (TAK)’s stock price range in the last year - US Post News

Inmode Ltd (INMD) Stock Price and Analyst Predictions - The News Heater

Recent Insider Activity Could Benefit Wabash National Corp (WNC) - Knox Daily

Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - Knox Daily

Japan’s Takeda launches innovation centre in Bengaluru; to hire 750 in 2025 - Deccan Herald

Weekly Upgrades and Downgrades - InvestorPlace

Amgen stock price formed a death cross: will it rebound in 2025? - MSN

Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

USFDA gives tentative approval to Lupin’s generic formulation to treat type 2 diabetes - The Financial Express

Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow

Things To Consider Before You Buy Takeda Pharmaceutical Co ADR (NYSE: TAK) - Stocks Register

Capital One Financial Corp (NYSE: COF): Overvalued In Comparison To Others? - Stocks Register

Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - MSN

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow

Australia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Denmark Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

Italy Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

UK Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

South Africa Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research

다케다약품공업 ADR (TAK) 재무 분석

매출

순이익

현금흐름

주당 순 이익

TAK과 유사한 종목